戻る Agenda
COVID-19: Lessons Learnt so far in the Regulatory and R&D
Session Chair(s)
Angelika Joos, MPharm
Executive Director, Science & Regulatory Policy
MSD, Belgium
Martine Zimmermann, PharmD
Senior Vice President, Head of Global Regulatory Affairs
Ipsen , France
In this session we are going cover: • Lessons learned from close collaboration between stakeholders and regulators globally to address the key regulatory and development changes during the COVID-19 pandemic; • Have precedents in regulatory flexibility (e.g. Ebola crisis) helped the regulatory ecosystem to face the current challenge and how? • Discuss how regulatory teams had to adapt to an unprecedented environment and need to deliver on such critical need, in particularly challenging circumstances; • How regulators worked together to foster consistent and harmonized actions globally, and what that might mean for regulatory science in the future.
Speaker(s)
Title to be Announced
Sofie Langereis
MSD, Netherlands
Regulatory Affairs Associate Liaison
Title to be Announced
Junko Sato, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Associate Executive Director
Title to be Announced
Fergus Sweeney, PhD
European Medicines Agency, Netherlands
Head of Clinical Studies and Manufacturing Task Force
Title to be Announced
Martine Zimmermann, PharmD
Ipsen , France
Senior Vice President, Head of Global Regulatory Affairs